Traynor Capital Management Inc. Buys 2,400 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Traynor Capital Management Inc. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 24,790 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the quarter. Regeneron Pharmaceuticals accounts for 1.2% of Traynor Capital Management Inc.’s investment portfolio, making the stock its 13th largest holding. Traynor Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $17,659,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Mizuho Securities USA LLC boosted its position in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares during the period. Principal Financial Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Simplify Asset Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after acquiring an additional 3,231 shares in the last quarter. Catalytic Wealth RIA LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $1,334,000. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 12.3% during the third quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock valued at $21,428,000 after purchasing an additional 2,234 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Bank of America restated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $680.03 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $74.73 billion, a PE ratio of 16.83, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10. The company’s 50 day moving average is $733.06 and its two-hundred day moving average is $943.95. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.